Examining the Evidence in Frontline Therapy

Managing Myeloma: Examining the Evidence in Frontline Therapy
Managing Myeloma: Examining the Evidence in Frontline Therapy
CME, CPE, CNE
Amrita Krishnan, MD, FACP and Saad Z. Usmani, MD, MBA, FACP
Release Date: January 30, 2023
Expiration Date: January 30, 2024

In recent years, important new advances have been reported in the frontline treatment of newly diagnosed multiple myeloma (NDMM) patients. Despite this progress, however, significant challenges remain. In this activity, two myeloma experts will discuss the most recent information and evidence regarding frontline therapy including selecting regimens based on individual patient disease factors, treatment regimens for transplant-ineligible and transplant-eligible patients, and key practice considerations for NDMM.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
CE ExpiredView Only, No Credit